Physician profile
Sandra E Saenz Rivera
NPI 1336827443
$627.98
in general payments reported to CMS, 2019-2025
15 companies · $614 in 2025
The $614 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $14.32 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $628.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $627.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $93.19 | 2025 | Injectafer |
| Alnylam Pharmaceuticals INC. | $90.99 | 2025 | Givlaari |
| Otsuka America Pharmaceutical, INC. | $87.17 | 2025 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $58.73 | 2025 | |
| Madrigal Pharmaceuticals | $43.33 | 2025 | Rezdiffra |
| Vanda Pharmaceuticals INC. | $40.27 | 2025 | Fanapt |
| Gilead Sciences, INC. | $39.08 | 2025 | Epclusa, Yeztugo |
| Lilly USA, LLC | $38.09 | 2025 | Kisunla |
| Abiomed | $29.62 | 2025 | |
| Astellas Pharma US INC | $26.84 | 2025 | Veozah |
| Corcept Therapeutics | $21.41 | 2025 | Korlym |
| Novo Nordisk INC | $15.48 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.05 | 2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $14.41 | 2025 | Airsupra |
| Sanofi-Aventis U.S. LLC | $14.32 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sandra Saenz Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.